Posted On: 03/15/2016 10:09:40 AM
Post# of 72446
Do we anticipate a B-OM interim report soon? I believe the enrollment started on May 26th, 2015, which is almost a year ago. I also remember the PRs below on August 3rd and February 26th which seems to suggest that the anti-inflammatory properties are showing up...then we have Dr. Sonis appointed to the SAB. Sure would be nice to wake up to a positive PR about B-OM soon!
August 3rd
"We are already confident in Brilacidin's anti-infective properties and believe it will be a true breakthrough if Brilacidin works as an anti-inflammatory as well," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "This trial has many implications because, as large as the anti-infective market is, the anti-inflammatory market potential for Brilacidin is even greater. I think it is important for shareholders to understand this and the potential value it brings to the Company."
Feb 26th
"Moreover, Brilacidin has activity against stationary phase bacteria, which play a role in persistent infections and biofilm formation. Finally, Brilacidin has anti-inflammatory properties that may accelerate and promote clinical healing."
August 3rd
"We are already confident in Brilacidin's anti-infective properties and believe it will be a true breakthrough if Brilacidin works as an anti-inflammatory as well," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "This trial has many implications because, as large as the anti-infective market is, the anti-inflammatory market potential for Brilacidin is even greater. I think it is important for shareholders to understand this and the potential value it brings to the Company."
Feb 26th
"Moreover, Brilacidin has activity against stationary phase bacteria, which play a role in persistent infections and biofilm formation. Finally, Brilacidin has anti-inflammatory properties that may accelerate and promote clinical healing."
(0)
(0)
